Update on COVID-19 vaccines and autoimmune-mediated rheumatic diseases

Lakshmanan Suresh

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology Supplements

Bieżący suplement Archiwum Reumatologia

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

NOWOŚĆ

Portal dla reumatologów!

www.ereumatologia.pl

Wyszukiwanie

1/2021

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Update on COVID-19 vaccines and autoimmune-mediated rheumatic diseases

Lakshmanan Suresh

¹

Department of Oral Diagnostic Sciences, University at Buffalo, NY, United States

Data publikacji online: 2021/09/08

Pełna treść artykułu Pobierz cytowanie

Providing lasting long-term immunity through effective vaccines for current and emerging strains of coronavirus disease 2019 (COVID-19) providing lasting long-term immunity is fundamental to overcoming the pandemic. Recently approved COVID-19 vaccines have brought tremendous promise to help end this pandemic. As of July 20, 2021, the main vaccines that have been approved for use in North America and Europe are the mRNA vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), and the viral vector vaccines ChAdOx1 (AstraZeneca) and Ad26.COV2.S (Johnson & Johnson) [1].

Update on COVID-19 vaccines and autoimmune-mediated rheumatic diseases

Lakshmanan Suresh 1

Lakshmanan Suresh

¹